Skip to Content
 
Daniel C.  Liebler

Daniel C. Liebler, Ph.D.

Director, Jim Ayers Institute for Precancer Detection and Diagnosis
Ingram Professor of Cancer Research
Professor of Biochemistry, Pharmacology, and Biomedical Informatics
Director, Center in Molecular Toxicology
Researcher

Contact Information:

Vanderbilt University Medical Center
465 21st Avenue South, U1213 MRB III
Nashville , TN 37232-6350
615-322-3063
Fax: 615-936-1001

Profile

Daniel C. Liebler is Ingram Professor of Cancer Research and Professor of Biochemistry, Pharmacology and Biomedical Informatics at the Vanderbilt University School of Medicine. After completing his doctoral training in pharmacology at Vanderbilt and postdoctoral training in biochemistry at Oregon State, he served on the faculty at the University of Arizona prior to joining the Department of Biochemistry and the Vanderbilt-Ingram Cancer Center in 2003. He is Director of the Jim Ayers Institute for Precancer Detection and Diagnosis at Vanderbilt, which is dedicated to the advancement of cancer diagnostics. He leads the Vanderbilt program in the National Cancer Institute-funded Clinical Proteomic Tumor Analysis Consortium (CPTAC) network, which is integrating proteomics with genomic technologies to understand the molecular drivers of cancer. Dr. Liebler is also the co-Director of the Vanderbilt Biomarker Developmental Laboratory in the NCI Early Detection Research Network. Dr. Liebler's research program has focused for over 25 years on toxicology, chemical biology and cancer biology, with an emphasis on application of mass spectrometry and proteomics.

Education
 
  • B.S. Chemistry, Villanova (1980)
  • Ph.D. Pharmacology, Vanderbilt (1984)
 
Research Description

Dr. Liebler’s research program addresses two broad problems that are linked by the application of analytical proteomics technologies, particularly mass spectrometry. The first problem is the development of protein biomarkers as diagnostics for early cancer detection and for guiding therapy of established disease. Application of standardized mass spectrometry-based proteomics technology platforms enables discovery and analytical validation of candidate biomarkers in human clinical specimens. Current work is directed at development of plasma-based diagnostics for early detection of colon and lung cancer and tumor tissue-based diagnostics for identifying high-risk cancers and predicting response to therapy.

The second problem is the role protein damage by reactive electrophiles in chemical toxicity and disease processes. This work involves development of methods to analyze modified and damaged proteins and to assess the impact of protein damage by reactive chemicals. Major areas of current focus are the characterization of global protein modification by endogenous lipid electrophiles in oxidative stress and the identification of signaling sensors targeted by electrophiles and the mechanisms by which chemical modification of these sensor proteins initiate stress responses.

Publications
  • Zimmerman LJ, Li M, Yarbrough WG, Slebos RJ, Liebler DC. Global stability of plasma proteomes for mass spectrometry-based analyses. Mol. Cell Proteomics [print-electronic]. 2012 Jun; 11(6): M111.014340. PMID: 22301387, PMCID: PMC3433892, PII: M111.014340, DOI: 10.1074/mcp.M111.014340, ISSN: 1535-9484.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22301387.
  • Schepeler T, Holm A, Halvey P, Nordentoft I, Lamy P, Riising EM, Christensen LL, Thorsen K, Liebler DC, Helin K, Ørntoft TF, Andersen CL. Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes. Oncogene [print-electronic]. 2012 May 5/31/2012; 31(22): 2750-60. PMID: 21963845, PII: onc2011453, DOI: 10.1038/onc.2011.453, ISSN: 1476-5594.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21963845.
  • Halvey PJ, Zhang B, Coffey RJ, Liebler DC, Slebos RJ. Proteomic consequences of a single gene mutation in a colorectal cancer model. J. Proteome Res [print-electronic]. 2012 Feb 2/3/2012; 11(2): 1184-95. PMID: 22103262, PMCID: PMC3271737, DOI: 10.1021/pr2009109, ISSN: 1535-3907.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22103262.
  • Wang X, Slebos RJ, Wang D, Halvey PJ, Tabb DL, Liebler DC, Zhang B. Protein identification using customized protein sequence databases derived from RNA-Seq data. J. Proteome Res [print-electronic]. 2012 Feb 2/3/2012; 11(2): 1009-17. PMID: 22103967, PMCID: PMC3727138, DOI: 10.1021/pr200766z, ISSN: 1535-3907.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22103967.
  • Myers MV, Manning HC, Coffey RJ, Liebler DC. Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling. Mol. Cell Proteomics [print-electronic]. 2012 Feb; 11(2): M111.015222. PMID: 22147731, PMCID: PMC3277773, PII: M111.015222, DOI: 10.1074/mcp.M111.015222, ISSN: 1535-9484.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22147731.
  • Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, Zimmerman LJ, Liebler DC, Slebos RJ, Lorkiewicz PK, Higashi RM, Fan TW, Dang CV. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012 Jan 1/4/2012; 15(1): 110-21. PMID: 22225880, PMCID: PMC3345194, PII: S1550-4131(11)00468-2, DOI: 10.1016/j.cmet.2011.12.009, ISSN: 1932-7420.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22225880.
  • Codreanu SG, Kim HY, Porter NA, Liebler DC. Biotinylated probes for the analysis of protein modification by electrophiles. Methods Mol. Biol. 2012; 803: 77-95. PMID: 22065220, PMCID: PMC3811082, DOI: 10.1007/978-1-61779-364-6_7, ISSN: 1940-6029.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22065220.
  • Johnson W, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of cyclomethicone, cyclotetrasiloxane, cyclopentasiloxane, cyclohexasiloxane, and cycloheptasiloxane. Int. J. Toxicol. 2011 Dec; 30(6 Suppl): 149S-227S. PMID: 22247236, PII: 30/6_suppl/149S, DOI: 10.1177/1091581811428184, ISSN: 1092-874X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22247236.
  • Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A, Fan F, Dallas N, Xia L, Gaur P, Samuel S, Liebler DC, Ellis LM. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Br. J. Cancer [print-electronic]. 2011 Nov 11/22/2011; 105(11): 1759-67. PMID: 22045189, PMCID: PMC3242606, PII: bjc2011449, DOI: 10.1038/bjc.2011.449, ISSN: 1532-1827.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22045189.
  • Ma ZQ, Tabb DL, Burden J, Chambers MC, Cox MB, Cantrell MJ, Ham AJ, Litton MD, Oreto MR, Schultz WC, Sobecki SM, Tsui TY, Wernke GR, Liebler DC. Supporting tool suite for production proteomics. Bioinformatics [print-electronic]. 2011 Nov 11/15/2011; 27(22): 3214-5. PMID: 21965817, PMCID: PMC3208394, PII: btr544, DOI: 10.1093/bioinformatics/btr544, ISSN: 1367-4811.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21965817.
  • Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, González-Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC, Arteaga CL. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene [print-electronic]. 2011 Oct 10/6/2011; 30(40): 4163-74. PMID: 21499296, PMCID: PMC3204390, PII: onc2011130, DOI: 10.1038/onc.2011.130, ISSN: 1476-5594.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21499296.
  • Burnett CL, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final report of the Amended Safety Assessment of PVM/MA copolymer and its related salts and esters as used in cosmetics. Int. J. Toxicol. 2011 Oct; 30(5 Suppl): 128S-44S. PMID: 22068629, PII: 30/5_suppl/128S, DOI: 10.1177/1091581811407934, ISSN: 1092-874X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22068629.
  • Hoofnagle AN, Aebersold R, Anderson NL, Felsenfeld A, Liebler DC. Painting a moving picture: large-scale proteomics efforts and their potential for changing patient care. Clin. Chem [print-electronic]. 2011 Oct; 57(10): 1357-60. PMID: 21540400, PII: clinchem.2010.158311, DOI: 10.1373/clinchem.2010.158311, ISSN: 1530-8561.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21540400.
  • Connor RE, Marnett LJ, Liebler DC. Protein-selective capture to analyze electrophile adduction of hsp90 by 4-hydroxynonenal. Chem. Res. Toxicol [print-electronic]. 2011 Aug 8/15/2011; 24(8): 1275-82. PMID: 21749116, PMCID: PMC3155980, DOI: 10.1021/tx200157t, ISSN: 1520-5010.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21749116.
  • Zhang B, Shi Z, Duncan DT, Prodduturi N, Marnett LJ, Liebler DC. Relating protein adduction to gene expression changes: a systems approach. Mol Biosyst [print-electronic]. 2011 Jul; 7(7): 2118-27. PMID: 21594272, PMCID: PMC3659419, DOI: 10.1039/c1mb05014a, ISSN: 1742-2051.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21594272.
  • Michaelson-Richie ED, Ming X, Codreanu SG, Loeber RL, Liebler DC, Campbell C, Tretyakova NY. Mechlorethamine-induced DNA-protein cross-linking in human fibrosarcoma (HT1080) cells. J. Proteome Res [print-electronic]. 2011 Jun 6/3/2011; 10(6): 2785-96. PMID: 21486066, PMCID: PMC3208907, DOI: 10.1021/pr200042u, ISSN: 1535-3907.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21486066.
  • Zhang H, Liu Q, Zimmerman LJ, Ham AJ, Slebos RJ, Rahman J, Kikuchi T, Massion PP, Carbone DP, Billheimer D, Liebler DC. Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry. Mol. Cell Proteomics [print-electronic]. 2011 Jun; 10(6): M110.006593. PMID: 21357624, PMCID: PMC3108838, PII: M110.006593, DOI: 10.1074/mcp.M110.006593, ISSN: 1535-9484.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21357624.
  • Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final report of the Cosmetic Ingredient Review Expert Panel safety assessment of polymethyl methacrylate (PMMA), methyl methacrylate crosspolymer, and methyl methacrylate/glycol dimethacrylate crosspolymer. Int. J. Toxicol. 2011 May; 30(3 Suppl): 54S-65S. PMID: 21772027, PII: 30/3_suppl/54S, DOI: 10.1177/1091581811407352, ISSN: 1092-874X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21772027.
  • Johnson W, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Amended safety assessment of Sesamum indicum (sesame) seed oil, hydrogenated sesame seed oil, Sesamum indicum (sesame) oil unsaponifiables, and sodium sesameseedate. Int. J. Toxicol. 2011 May; 30(3 Suppl): 40S-53S. PMID: 21772026, PII: 30/3_suppl/40S, DOI: 10.1177/1091581811406987, ISSN: 1092-874X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21772026.
  • Li J, Su Z, Ma ZQ, Slebos RJ, Halvey P, Tabb DL, Liebler DC, Pao W, Zhang B. A bioinformatics workflow for variant peptide detection in shotgun proteomics. Mol. Cell Proteomics [print-electronic]. 2011 May; 10(5): M110.006536. PMID: 21389108, PMCID: PMC3098595, PII: M110.006536, DOI: 10.1074/mcp.M110.006536, ISSN: 1535-9484.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21389108.